person · Reporting owner
Senner Christopher J.
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EXELIXIS, INC.EXEL · Entity 3386 | EVP and CFO | May 15, 2026 | May 19, 2026 |
| Quince Therapeutics, Inc.QNCX · Entity 7403 | Director | June 11, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EXELIXIS, INC.
Report date May 15, 2026 · Filed May 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 952,317 |
Last balance in matching sequence
After 2026-05-18 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-05-15 · Tax withholding · Disposed 40,892 · Balance 987,218 F1: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units ("RSUs") awarded on March 4, 2022, April 3, 2023, February 23, 2024, and February 26, 2025. F2: Includes 403,915 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and the performance-based restricted stock unit award granted to the Reporting Person on March 31, 2025 ("One-Time Award PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each One-Time Award PSU represents a contingent right to receive one share of Common Stock. Row 2 · 2026-05-18 · Sale · Disposed 34,901 · Balance 952,317 F3: Represents the weighted average sales price. The shares of Common Stock were sold in multiple transactions at prices ranging from $50.00 to $50.07. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. F2: Includes 403,915 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and the performance-based restricted stock unit award granted to the Reporting Person on March 31, 2025 ("One-Time Award PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each One-Time Award PSU represents a contingent right to receive one share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) | 2,723 |
Reported balance
Holding disclosure · report date 2026-05-15 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,723 F4: Represents shares of Common Stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of May 14, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units ("RSUs") awarded on March 4, 2022, April 3, 2023, February 23, 2024, and February 26, 2025.
F2: Includes 403,915 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of RSUs and the performance-based restricted stock unit award granted to the Reporting Person on March 31, 2025 ("One-Time Award PSUs"). Each RSU is the economic equivalent of one share of Common Stock and each One-Time Award PSU represents a contingent right to receive one share of Common Stock.
F3: Represents the weighted average sales price. The shares of Common Stock were sold in multiple transactions at prices ranging from $50.00 to $50.07. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
F4: Represents shares of Common Stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of May 14, 2026.
Quince Therapeutics, Inc.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2036-06-11 | Direct | 2,700 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 2,700 · Balance 2,700 F1: 100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 11, 2022 Filed Aug 13, 2022 00:23 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 225,000 | $0.00 Strike: $6.21 | $0.00 |
DisclosureSEC source: 0000939767-22-000100 · wf-form4_166035018251392.xml · derivative · entry 4 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 225,000 shares Expires 2022-09-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 225,000 shares of Common Stock, became fully exercisable on September 16, 2019. Read SEC document |
| August 11, 2022 Filed Aug 13, 2022 00:23 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 152,867 | $19.23 | $2,939,632.41 |
DisclosureSEC source: 0000939767-22-000100 · wf-form4_166035018251392.xml · nonDerivative · entry 2 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 518,015 F2 · shares: Represents a "net exercise" of an outstanding stock option. The Reporting Person received 225,000 shares of Common Stock on the net exercise of a stock option to purchase 72,133 shares of Common Stock. The Issuer withheld 152,867 shares of Common Stock underlying the stock option for payment of the exercise price and tax withholding using the closing price of Common Stock on August 11, 2022 of $19.23. Read SEC document |
| August 11, 2022 Filed Aug 13, 2022 00:23 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 225,000 | $6.21 | $1,397,250.00 |
DisclosureSEC source: 0000939767-22-000100 · wf-form4_166035018251392.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 670,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 166,412 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| August 03, 2022 Filed Aug 6, 2022 01:48 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 8,074 | $21.49 | $173,510.26 |
DisclosureSEC source: 0000939767-22-000088 · wf-form4_165975048260402.xml · nonDerivative · entry 2 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,882 F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on August 3, 2022. Read SEC document |
| August 03, 2022 Filed Aug 6, 2022 01:48 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 32,567 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-22-000088 · wf-form4_165975048260402.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 453,956 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: On September 11, 2020, the Reporting Person was granted a performance-based restricted stock unit award ("PSU") under the Exelixis, Inc. 2017 Equity Incentive Plan covering 65,135 shares of common stock (such shares, the "Target Shares"). The PSU generally vests as follows: (i) 50% of the Target Shares vest upon the Committee's certification of achievement of certain performance criteria as certified by the Compensation Committee (the "Committee"); and (ii) 50% of the Target Shares vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. In addition, the PSU provides for vesting of up to a maximum of 200% of the Target Shares depending on the timing and level of achievement of the performance criteria provided for under the PSU. F3 · shares: On August 3, 2022, the Committee determined that certain performance criteria had been achieved, resulting in the Reporting Person's eligibility to vest up to 50% of the Target Shares subject to the PSU. Accordingly, the Committee's certification resulted in the immediate vesting of 25% of the Target Shares, and 25% of the Target Shares will vest on August 15, 2023, subject to the Reporting Person's continuous service through that date. The Reporting Person remains eligible for additional vesting depending the level and timing of achievement of the performance criteria through December 31, 2024. F4 · balance_after: Includes 166,412 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 00:48 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001209191-22-035678 · doc4.xml · derivative · entry 1 Senner Christopher J. · CIK 0001648367 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2032-06-07 F1 · derivative.exercise_date: 100% of the shares subject to the stock option shall vest in full on the one-year anniversary of the grant date of June 8, 2022. Read SEC document |
| May 15, 2022 Filed May 18, 2022 00:23 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 8,444 | $20.08 | $169,555.52 |
DisclosureSEC source: 0000939767-22-000062 · wf-form4_165283339932086.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,389 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded March 4, 2021. F2 · balance_after: Includes 150,128 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 01:57 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 75,985 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-22-000038 · wf-form4_164679104886123.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 429,833 F1 · security: Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2023 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested. F3 · balance_after: Includes 166,165 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:04 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 15,626 | $18.59 | $290,487.34 |
DisclosureSEC source: 0000939767-22-000018 · wf-form4_164514623486592.xml · nonDerivative · entry 2 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,848 F3 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 20, 2019, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on February 3, 2021. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 01:04 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 2,701 | $18.59 | $50,211.59 |
DisclosureSEC source: 0000939767-22-000018 · wf-form4_164514623486592.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,474 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 10, 2018, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on February 3, 2021. F2 · balance_after: Includes 90,180 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| December 15, 2021 Filed Dec 18, 2021 01:32 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 5,131 | $17.00 | $87,227.00 |
DisclosureSEC source: 0000939767-21-000114 · wf-form4_163979112340680.xml · nonDerivative · entry 2 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 372,175 F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on December 15, 2021. Read SEC document |
| December 15, 2021 Filed Dec 18, 2021 01:32 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 19,491 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-21-000114 · wf-form4_163979112340680.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,306 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: On September 10, 2018, the Reporting Person was granted a performance-based restricted stock unit ("PSU") award under the Exelixis, Inc. 2017 Equity Incentive Plan covering 19,491 shares of common stock. The PSU award generally vests as follows: (i) 50% of the original number of shares subject to the award vest upon certification by the Compensation Committee (the "Committee") that Exelixis, Inc. has achieved certain performance criteria related to the submission of Investigational New Drug applications with the U.S. Food and Drug Administration, or equivalent applications or filings with a foreign governmental authority, with respect to product candidates discovered, in-licensed or acquired by Exelixis, Inc. (the "2018 PSU Goal"); and (ii) 50% of the original number of shares subject to the award will vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. F3 · shares: On December 15, 2021, the Committee convened to determine that the 2018 PSU Goal had been achieved, resulting in the immediate vesting of 50% of the PSU award, and the remaining 50% will vest on February 15, 2023, subject to the Reporting Person's continuous service through that date. F4 · balance_after: Includes 124,759 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 15, 2021 Filed Nov 18, 2021 01:39 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 46,920 | $18.10 | $849,252.00 |
DisclosureSEC source: 0000939767-21-000103 · wf-form4_163719952051824.xml · nonDerivative · entry 3 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 357,815 F4 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 20, 2019, for which the Compensation Committee certified that Exelixis, Inc. had achieved certain performance criteria on October 22, 2020. Read SEC document |
| November 15, 2021 Filed Nov 18, 2021 01:39 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 2,566 | $18.10 | $46,444.60 |
DisclosureSEC source: 0000939767-21-000103 · wf-form4_163719952051824.xml · nonDerivative · entry 2 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 404,735 F3 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 10, 2018, for which the Compensation Committee certified that Exelixis, Inc. had achieved the performance goal on September 2, 2020. Read SEC document |
| November 15, 2021 Filed Nov 18, 2021 01:39 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 8,227 | $18.10 | $148,908.70 |
DisclosureSEC source: 0000939767-21-000103 · wf-form4_163719952051824.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 407,301 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded on October 3, 2017. F2 · balance_after: Includes 115,013 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| September 30, 2021 Filed Oct 5, 2021 00:13 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 8,573 | $20.63 | $176,860.99 |
DisclosureSEC source: 0000939767-21-000087 · wf-form4_163339281116981.xml · nonDerivative · entry 2 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 415,528 F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on September 30, 2021. Read SEC document |
| September 30, 2021 Filed Oct 5, 2021 00:13 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 32,567 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-21-000087 · wf-form4_163339281116981.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 424,101 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: On September 11, 2020, the Reporting Person was granted a performance-based restricted stock unit award ("PSU") under the Exelixis, Inc. 2017 Equity Incentive Plan covering 65,135 shares of common stock (such shares, the "Target Shares"). The PSU generally vests as follows: (i) 50% of the Target Shares vest upon certification by the Compensation Committee (the "Committee") that Exelixis has achieved certain performance criteria; and (ii) 50% of the Target Shares vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. In addition, the PSU provides for vesting of up to a maximum of 200% of the Target Shares depending on the timing and level of achievement of the performance criteria provided for under the PSU. F3 · shares: On September 30, 2021, the Committee determined that certain performance criteria had been achieved, resulting in the Reporting Person's eligibility to vest up to 50% of the Target Shares subject to the PSU. Accordingly, the Committee's certification resulted in the immediate vesting of 25% of the Target Shares, and 25% of the Target Shares will vest on November 15, 2022, subject to the Reporting Person's continuous service through that date. The Reporting Person remains eligible for additional vesting depending the level and timing of achievement of the performance criteria through December 31, 2024. F4 · balance_after: Includes 224,627 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| September 21, 2021 Filed Sep 24, 2021 00:16 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 90,000 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0000939767-21-000083 · wf-form4_163244255527325.xml · derivative · entry 4 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,000 shares Expires 2022-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 350,000 shares of Common Stock, became fully exercisable on July 15, 2019. Read SEC document |
| September 21, 2021 Filed Sep 24, 2021 00:16 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 55,057 | $20.33 | $1,119,308.81 |
DisclosureSEC source: 0000939767-21-000083 · wf-form4_163244255527325.xml · nonDerivative · entry 2 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 391,534 F2 · kind: Represents a "net exercise" of an outstanding stock option. The Reporting Person received 34,943 shares of Common Stock on the net exercise of a stock option to purchase 90,000 shares of Common Stock. The Issuer withheld 55,057 shares of Common Stock underlying the stock option for payment of the exercise price and tax withholding using a stock price on September 21, 2021 of $20.33. Read SEC document |
| September 21, 2021 Filed Sep 24, 2021 00:16 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 90,000 | $3.66 | $329,400.00 |
DisclosureSEC source: 0000939767-21-000083 · wf-form4_163244255527325.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 446,591 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 208,343 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| June 16, 2021 Filed Jun 17, 2021 23:32 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (right to buy) · Derivative | 11,029 | $0.00 Strike: $50.56 | $0.00 |
DisclosureSEC source: 0001209191-21-041719 · doc4.xml · derivative · entry 1 Senner Christopher J. · CIK 0001648367 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,029 Underlying: Common Stock · 11,029 shares Expires 2031-06-15 F1 · derivative.exercise_date: 100% of the shares subject to the stock option shall vest in full on the one-year anniversary of the grant date of June 16, 2021. Read SEC document |
| March 04, 2021 Filed Mar 6, 2021 01:00 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 64,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-21-000033 · wf-form4_161499238918592.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,591 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on May 15, 2022 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested. F3 · balance_after: Includes 208,343 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 15, 2021 Filed Feb 18, 2021 01:13 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 4,105 | $21.91 | $89,940.55 |
DisclosureSEC source: 0000939767-21-000019 · wf-form4_161361078108099.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,441 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 10, 2018, for which the Compensation Committee certified that Exelixis, Inc. had achieved the performance goal on December 4, 2019. F2 · balance_after: Includes 144,193 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 03, 2021 Filed Feb 6, 2021 02:14 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 18,206 | $22.56 | $410,727.36 |
DisclosureSEC source: 0000939767-21-000008 · wf-form4_161257763546589.xml · nonDerivative · entry 3 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,546 F8 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on February 3, 2021. Read SEC document |
| February 03, 2021 Filed Feb 6, 2021 02:14 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 59,411 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-21-000008 · wf-form4_161257763546589.xml · nonDerivative · entry 2 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,752 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F5 · date: On September 20, 2019, the Reporting Person was granted a PSU award the under 2017 Equity Incentive Plan covering 118,821 shares of common stock (such award, the "2019 Award," and such shares, the "Target Shares"). The 2019 Award generally vests as follows: (i) 50% of the Target Shares vest upon the Committee's certification of achievement certain performance criteria as certified by Committee; and (ii) 50% of the Target Shares vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. In addition, the 2019 Award provides for vesting of up to a maximum of 200% of the Target Shares depending on the timing and level of achievement of the performance criteria provided for under the 2019 Award. F6 · shares: On February 3, 2021, the Committee determined the maximum performance criteria had been achieved, resulting in the Reporting Person's eligibility to vest up to 200% of the Target Shares subject to the 2019 Award. Accordingly, the Committee's certification resulted in the immediate vesting of 25% of the Target Shares, and the remaining 25% of the Target Shares will vest on February 15, 2022, subject to the Reporting Person's continuous service through that date. F7 · balance_after: Includes 151,989 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| February 03, 2021 Filed Feb 6, 2021 02:14 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 9,745 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-21-000008 · wf-form4_161257763546589.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,341 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: On September 10, 2018, the Reporting Person was granted a performance-based restricted stock unit ("PSU") award under the Exelixis, Inc. 2017 Equity Incentive Plan covering 9,745 shares of common stock (such award, the "2018 Award"). The 2018 Award generally vests as follows: (i) 50% of the original number of shares subject to the 2018 Award vest upon certification by the Compensation Committee (the "Committee") that Exelixis has achieved certain performance criteria related to clinical trial enrollment or positive top-line results (the "2018 Goal"); and (ii) 50% of the original number of shares subject to the 2018 Award will vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. F3 · shares: On February 3, 2021, the Committee convened to determine that the 2018 Goal had been achieved, resulting in the immediate vesting of 50% of the 2018 Award, and the remaining 50% will vest on February 15, 2022, subject to the Reporting Person's continuous service through that date F4 · balance_after: Includes 122,283 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| January 12, 2021 Filed Jan 15, 2021 01:22 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 30,000 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0000939767-21-000006 · wf-form4_161067375022456.xml · derivative · entry 4 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 30,000 shares Expires 2022-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 350,000 shares of Exelixis, Inc. common stock, became fully exercisable on July 15, 2019 Read SEC document |
| January 12, 2021 Filed Jan 15, 2021 01:22 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 30,000 | $25.00 | $750,000.00 |
DisclosureSEC source: 0000939767-21-000006 · wf-form4_161067375022456.xml · nonDerivative · entry 2 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,596 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2020 Read SEC document |
| January 12, 2021 Filed Jan 15, 2021 01:22 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 30,000 | $3.66 | $109,800.00 |
DisclosureSEC source: 0000939767-21-000006 · wf-form4_161067375022456.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 117,410 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| November 15, 2020 Filed Nov 18, 2020 01:07 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 2,633 | $20.16 | $53,081.28 |
DisclosureSEC source: 0000939767-20-000155 · wf-form4_160566165871278.xml · nonDerivative · entry 3 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,596 F4 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded on September 22, 2016. Read SEC document |
| November 15, 2020 Filed Nov 18, 2020 01:07 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 8,227 | $20.16 | $165,856.32 |
DisclosureSEC source: 0000939767-20-000155 · wf-form4_160566165871278.xml · nonDerivative · entry 2 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,229 F3 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of restricted stock units awarded on October 3, 2017. Read SEC document |
| November 15, 2020 Filed Nov 18, 2020 01:07 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 2,737 | $20.16 | $55,177.92 |
DisclosureSEC source: 0000939767-20-000155 · wf-form4_160566165871278.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,456 F1 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of performance-based restricted stock units awarded on September 10, 2018, for which the Compensation Committee certified that Exelixis, Inc. had achieved the performance goal on September 12, 2019. F2 · balance_after: Includes 117,410 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| October 22, 2020 Filed Oct 27, 2020 00:00 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 46,920 | $21.79 | $1,022,386.80 |
DisclosureSEC source: 0000939767-20-000137 · wf-form4_160375683228815.xml · nonDerivative · entry 2 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,193 F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on October 22, 2020. Read SEC document |
| October 22, 2020 Filed Oct 27, 2020 00:00 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 178,231 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-20-000137 · wf-form4_160375683228815.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,113 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: On September 20, 2019, the Reporting Person was granted a performance-based restricted stock unit award ("PSU") under the Exelixis, Inc. 2017 Equity Incentive Plan covering 118,821 shares of common stock (such shares, the "Target Shares"). The PSU generally vests as follows: (i) 50% of the Target Shares vest upon the Committee's certification of achievement certain performance criteria as certified by the Compensation Committee (the "Committee"); and (ii) 50% of the Target Shares vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. In addition, the PSU provides for vesting of up to a maximum of 200% of the Target Shares depending on the timing and level of achievement of the performance criteria provided for under the PSU. F3 · shares: On October 22, 2020, the Committee determined that certain performance criteria had been achieved, resulting in the Reporting Person's eligibility to vest up to 150% of the Target Shares subject to the PSU. Accordingly, the Committee's certification resulted in the immediate vesting of 75% of the Target Shares, and 75% of the Target Shares will vest on November 15, 2021, subject to the Reporting Person's continuous service through that date. The Reporting Person remains eligible for additional vesting depending the level and timing of achievement of the performance criteria through December 31, 2021. F4 · balance_after: Includes 143,233 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| October 08, 2020 Filed Oct 10, 2020 00:04 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 10,000 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0000939767-20-000134 · wf-form4_160228823687027.xml · derivative · entry 4 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 10,000 shares Expires 2022-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 350,000 shares of Exelixis, Inc. common stock, became fully exercisable on July 15, 2019. Read SEC document |
| October 08, 2020 Filed Oct 10, 2020 00:04 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 10,000 | $25.00 | $250,000.00 |
DisclosureSEC source: 0000939767-20-000134 · wf-form4_160228823687027.xml · nonDerivative · entry 2 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,882 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2020. F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.01. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| October 08, 2020 Filed Oct 10, 2020 00:04 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 10,000 | $3.66 | $36,600.00 |
DisclosureSEC source: 0000939767-20-000134 · wf-form4_160228823687027.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 54,117 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 00:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0000939767-20-000129 · wf-form4_160021461881803.xml · derivative · entry 4 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 20,000 shares Expires 2022-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing the right to purchase a total of 350,000 shares of Exelixis, Inc. common stock, became fully exercisable on July 15, 2019. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 00:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 20,000 | $25.00 | $500,000.00 |
DisclosureSEC source: 0000939767-20-000129 · wf-form4_160021461881803.xml · nonDerivative · entry 2 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,882 F2 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 29, 2020. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 00:03 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 20,000 | $3.66 | $73,200.00 |
DisclosureSEC source: 0000939767-20-000129 · wf-form4_160021461881803.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 54,117 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| September 02, 2020 Filed Sep 4, 2020 22:36 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 2,566 | $21.58 | $55,374.28 |
DisclosureSEC source: 0000939767-20-000124 · wf-form4_159925894699524.xml · nonDerivative · entry 2 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,882 F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on September 2, 2020. Read SEC document |
| September 02, 2020 Filed Sep 4, 2020 22:36 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 9,745 | $0.00 | $0.00 |
DisclosureSEC source: 0000939767-20-000124 · wf-form4_159925894699524.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,448 F1 · security: Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock. F2 · date: On September 10, 2018, the Reporting Person was granted a performance-based restricted stock unit ("PSU") award of 9,745 shares of common stock under the Exelixis, Inc. 2017 Equity Incentive Plan. Vesting of the PSU award is tied to performance goals set by the Compensation Committee (the "Committee") as follows: (i) 50% of the original number of shares subject to the award will vest upon the Committee's certification that a target number of potentially label-enabling clinical trials evaluating cabozantinib (both alone or in combination with another therapy) have been initiated; and (ii) 50% of the original number of shares subject to the award will vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification. F3 · shares: On September 2, 2020, the Committee convened to determine that the target number of clinical trial initiations had been achieved, resulting in the immediate vesting of 50% of the PSU award, and the remaining 50% will vest on November 15, 2021, subject to the Reporting Person's continuous service through that date. F4 · balance_after: Includes 54,117 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| June 08, 2020 Filed Jun 10, 2020 00:20 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | GrantStock Option (Right to Buy) · Derivative | 11,029 | $0.00 Strike: $41.73 | $0.00 |
DisclosureSEC source: 0001209191-20-035424 · doc4.xml · derivative · entry 1 Senner Christopher J. · CIK 0001648367 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,029 Underlying: Common Stock · 11,029 shares Expires 2030-06-07 F1 · derivative.exercise_date: This option shall fully vest on the one-year anniversary of the grant date, subject to the reporting person's continued services as a member of the board of directors of Cortexyme, Inc. through such vesting date. Read SEC document |
| May 08, 2020 Filed May 9, 2020 01:22 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 78,583 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0000939767-20-000075 · wf-form4_158898730774345.xml · derivative · entry 7 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 78,583 shares Expires 2022-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 350,000 shares of Exelixis, Inc. common stock, became fully exercisable on July 15, 2019. Read SEC document |
| May 08, 2020 Filed May 9, 2020 01:22 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 78,583 | $25.81 | $2,028,227.23 |
DisclosureSEC source: 0000939767-20-000075 · wf-form4_158898730774345.xml · nonDerivative · entry 4 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,703 F3 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.51 to $25.97. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4. Read SEC document |
| May 08, 2020 Filed May 9, 2020 01:22 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 78,583 | $3.66 | $287,613.78 |
DisclosureSEC source: 0000939767-20-000075 · wf-form4_158898730774345.xml · nonDerivative · entry 3 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,286 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2020 Filed May 9, 2020 01:22 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionOption (right to buy) · Derivative | 21,417 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0000939767-20-000075 · wf-form4_158898730774345.xml · derivative · entry 6 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,583 Underlying: Common Stock · 21,417 shares Expires 2022-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing the right to purchase a total of 350,000 shares of Exelixis, Inc. common stock, became fully exercisable on July 15, 2019. Read SEC document |
| May 07, 2020 Filed May 9, 2020 01:22 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 21,417 | $25.80 | $552,558.60 |
DisclosureSEC source: 0000939767-20-000075 · wf-form4_158898730774345.xml · nonDerivative · entry 2 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,703 F2 · price: Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $25.75 to $25.99. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 2 to this Form 4. Read SEC document |
| May 07, 2020 Filed May 9, 2020 01:22 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Exercise / conversionCommon Stock | 21,417 | $3.66 | $78,386.22 |
DisclosureSEC source: 0000939767-20-000075 · wf-form4_158898730774345.xml · nonDerivative · entry 1 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 49,244 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Read SEC document |
| December 04, 2019 Filed Dec 7, 2019 00:13 UTC | EXELIXIS, INC. EXEL · Entity 3386 | Tax withholdingCommon Stock | 4,090 | $17.67 | $72,270.30 |
DisclosureSEC source: 0000939767-19-000200 · wf-form4_157567759875228.xml · nonDerivative · entry 2 Senner Christopher J. · CIK 0001648367 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,703 F5 · shares: Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on December 4, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.